Adjunction of inhaled amikacin to intravenous standard-of-care antibiotics do not modified short term prognosis of Ventilator Associated Pneumonia due to Gram-negative bacilli.
Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial.
Rédigé par : Dr Olivier Leroy
The ESCMID recommendations published in 2017 (ATB-VAC 31/5/2017) are clear: the use of inhaled antibiotics in ICU should be prohibited. The Infectious Diseases Society of America and American Thoracic Society (IDSA/ATS) guidelines, suggest that VAP due to Gram-negative bacilli that are susceptible to only aminoglycosides or polymyxins should be treated with both inhaled and intravenous antibiot...
Ce contenu est à destination des professionnels de santé. Merci de vous identifier.
This content is intended for healthcare professionals. Thank you for identifying yourself.
This content is intended for healthcare professionals. Thank you for identifying yourself.
Déjà inscrit / Already registered ?
Créer un compte / Create an account
Créer un compte ne prend que quelques minutes et vous permettra d'accèder à l'ensemble des contenus du site.
Creating an account takes only instant and will allow you to access all the content of the website.